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Abstract: Mutations in the hepatocyte nuclear factor 4α (HNF4α) gene affect prenatal and postnatal 
pancreas development, being characterized by insulin-producing β-cell dysfunction. Little is 
known about the cellular and molecular mechanisms leading to β-cell failure as result of HNF4α 
mutation. In this study, we compared the miRNA profile of differentiating human induced 
pluripotent stem cells (hiPSC) derived from HNF4α+/Δ mutation carriers and their family control 
along the differentiation timeline. Moreover, we associated this regulation with the corresponding 
transcriptome profile to isolate transcript–miRNA partners deregulated in the mutated cells. This 
study uncovered a steep difference in the miRNA regulation pattern occurring during the posterior 
foregut to pancreatic endoderm transition, defining early and late differentiation regulatory 
windows. The pathway analysis of the miRNAome–transcriptome interactions revealed a likely 
gradual involvement of HNF4α+/Δ mutation in p53-mediated cell cycle arrest, with consequences 
for the proliferation potential, survival and cell fate acquisition of the differentiating cells. The 
present study is based on bioinformatics approaches and we expect that, pending further 
experimental validation, certain miRNAs deregulated in the HNF4α+/Δ cells would prove useful for 
therapy. 
Keywords: miRNA; hiPSC; HNF4α; MODY1; insulin-producing cells; in-vitro differentiation; 
endocrine; progenitor; pancreas; pluripotent stem cells 
 
1. Introduction 
Numerous studies aimed at deciphering the molecular regulation of various biological 
processes have proven that, besides protein–protein interactions, microRNAs (miRNAs) are also 
essential for regulating cellular molecular machinery. miRNAs are 19–22-nucleotide noncoding 
RNAs that regulate gene expression post-transcriptionally by base pairing with complementary 
sequences in the 3′ untranslated regions (3′UTRs) of protein-coding transcripts, thereby usually 
inhibiting their translation and/or stability [1]. Some of these noncoding RNA molecules have 
already been shown to play major roles in the regulation of β-cell development [2–4], maintenance 
and function [5–7], including insulin secretion [8] and circadian clocks [9]. The significance of 
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miRNAs during in-vitro differentiation to insulin-expressing cells was previously illustrated by 
experiments in human pluripotent stem cells, which showed that miR-200a has a critical role in 
regulating both epithelial–mesenchymal transition and definitive endoderm formation through 
direct repression of ZEB2 and SOX17, while miR30d and let-7e regulate the pancreatic progenitor 
gene RFX6 during late-stage differentiation [10]. Other studies showed that healthy hiPSCs [11] 
differentiating into insulin-producing cells presented a specific signature during this process, and 
the differentially expressed miRNA target genes were involved in endocrine pancreatic 
organogenesis. For example, miRNA-690 was shown to regulate induced pluripotent stem cells’ 
(iPSCs) differentiation into insulin-producing cells by targeting Sox9, previously linked to 
proliferation and differentiation of endocrine progenitors [12]. Moreover, the miR-302 cluster, 
previously involved in pluripotent stem cell maintenance and in the acquisition of undifferentiated 
phenotype, was also shown to have a role in the in-vitro dedifferentiation of human pancreatic islet 
cells [13]. All these studies indicate that a certain cell fate choice can be defined by a particular 
miRNA signature [14]. However, specific alterations of the miRNA cellular landscape in different 
forms of diabetes are yet to be investigated. 
Mutations in the hepatocyte nuclear factor 4A (HNF4α) gene lead to maturity-onset diabetes of 
the young (MODY)-1, characterized by pancreatic beta cell dysfunction affecting both prenatal and 
postnatal pancreas development [15]. Despite the comprehensive characterization of the mutation 
sites leading to the diabetic condition, very little is known about the cellular and molecular 
mechanisms responsible for the disease’s onset and progression. The main limitations are the ethical 
concerns regarding research on patients as well as the lack of suitable animal models [16–19]. 
Consequently, efforts are being made to employ human induced pluripotent stem cells (hiPSCs) as a 
model system for diabetes development. This is achieved by guiding human hiPS-cells derived from 
MODY1 families (i.e, mutation carrier patients and healthy control siblings) through fetal pancreas 
development in a stepwise fashion [20]. It is expected, but not yet demonstrated, that mature β-cells 
derived from MODY1 patients’ hiPSCs should mirror the reduced insulin secretion observed in 
MODY1 patients. Correspondingly, comparative analysis of MODY1-iPSC-derived pancreatic cell 
stages and lines may reveal the underlying, disease-specific mechanisms and pathways. We 
previously showed that insulin-positive cells could be generated in vitro from hiPSCs derived from 
patients carrying a nonsense HNF4α mutation, proving that the heterozygous state of p.Ile271fs 
mutation in human HNF4α is neither blocking the expression of the insulin genes nor the in-vitro 
development of insulin-producing cells [21]. Another study also showed that loss of 
HNF4α-mediated gene regulation affected foregut endoderm gene expression signatures, impairing 
liver and pancreas cell differentiation [22]. Recently, HNF4α was involved in controlling cell fate 
selection of pancreatic progenitors in vivo, upon transplantation in live hosts, by confining the 
hormone expression choice [23].  
Here, we present miRNA signatures of MODY1-hiPSC spanning seven stages of in-vitro 
differentiation along the pancreatic beta cell lineage (from definitive endoderm to 
hormone-expressing maturing endocrine islet cells) in samples derived from a MODY1 family 
(healthy control sibling (C) and two mutation carriers, HNF4α+/Δ). We show that the miRNA 
landscape in MODY1-generated differentiating cells is different from that in healthy hiPSC-derived 
hormone-producing islet cells and that their expression profile is drastically changed during the 
transition from the posterior gut to the pancreatic endoderm, defining two differentiation windows 
based on their regulation pattern. Moreover, by superimposing the corresponding transcriptome 
landscape, we performed the pathway analysis of these early and late differentiation windows and 
focused on transcript–miRNA couples deregulated in the mutated cells. 
2. Experimental Section 
2.1. Cell Source 
The experiments performed in this study were approved by the Norwegian Regional 
Committee of Medical and Health Research Ethics (5 October 2010, REK 2010/2295) and were 
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performed in accordance with the Helsinki Declaration, and informed consent was obtained from 
the patients and healthy donors. We used human induced pluripotent stem cells (hiPSCs) previously 
reprogrammed from skin fibroblasts donated by two HNF4α mutation carriers (male patients) and 
one family male sibling (healthy control) [21]. The characteristics of the donors are presented below, 
in Table 1. 
Table 1. Donor patients and healthy sibling details. 
Name Age  Gender Family Relation Mutation  
Donor 1 51 male father Heterozygous p.Ile271fs 
Donor 2 26 male son Heterozygous p.Ile271fs 
Donor 3 31 male son none 
The iPSCs cell lines were characterized and confirmed to have a normal karyotype and to be 
mycoplasma free using a MycoAlert Mycoplasm Detection Kit (Lonza, Basel, Switzerland, 
LT07-418). All hiPSC lines were assessed for pluripotency and enriched in SSEA4+ population 
(SSEA4 microbeads, 130097855, Miltenyi Biotec Norden, Lund, Sweden) before differentiation. 
2.2. In-Vitro Differentiation 
All three iPSC lines were differentiated in parallel on Matrigel-coated 6-well plates for the 
duration of the entire differentiation (28 days). iPSCs were maintained in mTeSR medium 
(STEMCELL Technologies, Vancouver, BC, Canada, cat. no. 85850) on a thin layer of Matrigel 
Basement Membrane Matrix Growth Factor Reduced (40 µg/cm2, Corning, NY, USA, cat. no. 
356230). 
At 48 h before differentiation, iPSC cultures of about 75% confluence were rinsed with 1× DPBS 
without Mg2+ and Ca2+ (Sigma, St. Louis, MO, USA, cat. no. D8537), followed by incubation with 
TrypLE Express Enzyme (1×) (Gibco, Carlsbad, CA, USA, cat. no. 12563-011) for 4–5 min at 37 °C. 
Single iPSCs were collected in mTeSR medium and spun down at 500g for 5 min. The resulting cell 
pellet was resuspended in mTeSR medium supplemented with 10mM ROCK inhibitor Y-27632 
(Sigma, St. Louis, MO, USA, cat. no. Y0503), and the single-cell suspension was seeded at ~1.5–2 × 106 
cells/well on Matrigel-coated 6-well plates. The mTeSR medium was changed once following 
seeding, resulting in about 90% confluence per well before differentiation started at 48 h 
post-seeding. 
Days 1–3: Undifferentiated hiPSCs were cultivated in the differentiation medium, containing 
MCDB131 medium (Life Technologies, Carlsbad, CA, USA, cat. no. 10372-019), 1.5 g/L sodium 
bicarbonate (Sigma, St. Louis, MO, USA, cat. no. S6297), 1× Glutamax (Life Technologies, cat. no. 
35050-079), 10mM glucose (Sigma, St. Louis, Missouri, USA, cat. no. G7021) concentration and 0.5% 
BSA (Sigma, St. Louis, MO, USA, cat. no. A7030). For day 1 and day 2 the medium was 
supplemented with 100 ng/mL Activin A (PeproTech Nordic, Stockholm, Sweden, cat. no. 120-14) 
and 0.3µM CHIR-99021 (Selleckchem, Houston, TX, USA, cat. no. S2924). For day 3 only, 100 ng/mL 
Activin A was added to the differentiation medium. Samples for RNA extraction were collected at 
the end of day 3 (for stage 1: definitive endoderm) following incubation with TrypLE Express 
Enzyme (1×) for 5 min at 37 °C. Single iPSCs were collected in PBS, spun down at 250× g for 5 min, 
resuspended in 70 µL of lysis buffer (Qiagen, Hilden, Germany, miRNeasy cat. no. 217084) and 
stored at −80 °C until use for RNA extraction. 
Days 4–5: For the differentiation towards primitive gut tube, the cells were cultivated in the 
differentiation MCDB131 medium supplemented with 0.25 mM Ascorbic acid (Sigma, St. Louis, MO, 
USA, cat. no. A4544) and 50ng/mL FGF7 (PeproTech Nordic, Stockholm, Sweden, cat. no. 100-19) for 
2 days. The medium was changed once. At the end of day 5, samples were collected and stored as 
described above. 
Days 6–7: Cells were further cultivated in the differentiation MCDB131 medium with 2.5 g/L 
sodium bicarbonate, 1× Glutamax, 10 mM glucose, 2% BSA, 1 mM retinoic acid (RA; Sigma, St. 
Louis, MO, USA, cat. no. R2625), 0.25 mM ascorbic acid, 50 ng/mL of FGF7, 0.25 mM SANT-1 (Sigma, 
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St. Louis, MO, USA, cat. no. S4572), 100nM LDN193189 (BMP receptor inhibitor, Stemgent, 
Cambridge, MA, USA, cat. no. 24804-0079), 1:200 ITS-X (Life Technologies, Carlsbad, CA, USA, cat. 
no. 51500056), and 200 nM TPB (PKC activator; Tocris, Bristol, United Kingdom, cat. no. 5343). The 
medium was changed every day. Samples of posterior foregut were collected at the end of day 7 and 
processed as described above. 
Days 8–10: Cells were cultivated in the above medium with the following changes: 2 ng/mL of 
FGF7, 0.1mM retinoic acid, 200 nM LDN193189, and 100 nM TPB. Samples of pancreatic endoderm 
were collected at the end of day 10. 
Days 11–13: S4 cells were cultivated further in MCDB131 medium with 1.5g/L sodium 
bicarbonate, 1× Glutamax, 20 mM glucose, 2% BSA, 0.25 mM SANT-1, 0.05 mM retinoic acid, 100nM 
LDN193189, 1:200 ITS-X, 1mM 3,3′,5-Triiodo-l-thyronine sodium salt (T3, Sigma, St. Louis, MO, 
USA, cat. no. T6397), 10 mM ALK5 inhibitor II (Enzo Life Sciences, Farmingdale, NY, USA, cat. no. 
ALX-270-445), 10mM zinc sulfate (Sigma, St. Louis, MO, USA, cat. no. Z0251) and 10 mg/mL of 
heparin (Sigma, St. Louis, MO, USA, cat. no. H3149). At the end of day 13, samples of pancreatic 
endocrine precursors were collected as described above. 
Days 14–20: Cells were further differentiated in MCDB131 with 1.5 g/L sodium bicarbonate, 1× 
Glutamax, 20 mM glucose, 2% BSA, 1:200 ITS-X, 1mM T3, 100 nM LDN193189, 10mM ALK5 
inhibitor II, 10mM zinc sulfate, 100 nM gamma secretase inhibitor (EMD Millipore/MERCK, 
Darmstadt, Germany, cat. no. 565789) and 10mg/mL of heparin. At the end of day 20, samples of 
immature hormone expressing islet-like cells were collected as described above. 
Days 21–28: Cells were further differentiated in MCDB131 supplemented with 1.5g/L sodium 
bicarbonate, 1× Glutamax, 20 mM final glucose concentration, 2% BSA, 1:200 ITS-X, 1 mM T3, 10 mM 
ALK5 inhibitor II, 10 mM zinc sulfate, 1 mM N-acetyl cysteine (N-Cys, Sigma, St. Louis, Missouri, 
USA, cat. no. A9165), 10 mM Trolox (Vitamin E analogue, EMD Millipore/MERCK, Darmstadt, 
Germany, cat. no. 648471), 2 mM R428 (AXL inhibitor, SelleckChem, Houston, TX, USA, cat. no. 
S2841) and 10 mg/mL of heparin. At the end of day 28, samples of maturing hormone-producing 
islet-like cells were collected as described above. 
2.3. RNA Extraction 
Samples representing one to six replicates of hiPSCs differentiating towards pancreatic islet-like 
cells (stages 1–7) were thawed on ice, and RNA was extracted using miRNeasy Micro (Qiagen, 
Hilden, Germany, cat. no. 217084) following the manufacturer’s instructions. Genomic DNA was 
removed using an RNase-free DNase Set (Qiagen, Hilden, Germany, cat. no. 79254). Total RNA 
concentration and integrity were checked using QIAxcel (Qiagen, Hilden, Germany,) and a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
2.4. miRNA Detection and Bioinformatics Analyses 
Detection of miRNA was performed using the nCounter (NanoString, Seattle, WA, USA) at the 
Genomic Platform (University of Geneva). We analyzed RNA samples for miRNA using a human 
miRNA kit codeset NS_H_miR_v3a consisting of probes specific for 798 miRNAs, according to the 
manufacturer’s instructions (NanoString, Seattle, WA, USA). The reaction was carried out with 100 
ng of the total RNA isolated as described above. The raw output .RCC files are available upon 
request. Pre-processing was performed as instructed by Nanostring for background correction. The 
Nanostring CodeSet contains negative controls, which are not specific to a target gene but contain 
alien sequences. The correction was done by subtracting the average signal plus 2 stdev of the 
negative controls from each miRNA in the dataset. The observed values less than 1 were given a 
threshold value of 1 in order to avoid negative values after log2 transformation. The log2 
transformation was performed by importing the data in R bioconductor. The PCA and hierarchical 
clustering were performed using GeneSpring software (version 14.9.1 GX, Agilent Technologies, 
Santa Clara, CA, USA), with clustering on both entities and conditions, using the differential 
distance metric and Ward’s linkage rule. Differentially expressed miRNAs were identified using 
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GeneSpring (fold change ≥ 1.5, p value ≤ 0.05), while TargetScan and microRNA.org were used to 
select target genes of differentially expressed miRNAs. 
2.5. RNAseq and Bioinformatics Analyses 
Total RNA samples were processed at the Genomic Platform (University of Geneva, 
Switzerland), using a HiSeq4000 machine (library UCSC-hg38), with 18 indexed libraries in two 
lanes using Illumina TruSec stranded mRNA (100 single-end reads) following the same procedure as 
described before [24,25]. Briefly, sequencing QC was done with FASTQC v.0.11.2. Reads were 
mapped with TopHat v2.0.13 default parameters to the reference genome on new junctions and 
known annotations. Biological QC and summarization were done with PicardTools v.1.80. Tables of 
counts were produced for aligned reads by Python software htseq-count v.0.0.6.1 with the reference 
gtf file (the multiple-mapping reads were not taken into account into the count table). The 
normalization and differential expression analysis were performed using the R-Bioconductor 
package EdgeR v.3.10.5 for the genes annotated in the reference genome. Hierarchical clustering was 
performed on both entities and conditions using GeneSpring GX version 14.9.1 GX (Agilent 
Technologies), using Ward’s method and differential metrics. The pathway analysis was performed 
using the Ingenuity Pathway Analysis program (IPA®, QIAGEN Redwood City, CA, USA) [26], as 
described in [25]. Briefly, we considered direct and indirect relationships, 35 molecules/network (25 
networks), and all node types and data sources, and restricted the confidence to experimentally 
observed only. 
2.6. Immunofluorescence Staining  
Differentiating cells were cultivated on Matrigel-covered glass coverslips (12 mm in diameter). 
At the end of each differentiation stage, the coverslips were washed three times with PBS (1×) and 
fixed with 4% paraformaldehyde for 15 min at room temperature. Then, cells were permeabilized by 
incubation with 1% Triton X-100 in 1× PBS for 15 min at room temperature. Cells were washed three 
times with 1× PBS and blocked with 2% BSA in 1× PBS for 1 h. Cells were incubated at 4 °C overnight 
with the following primary antibodies: goat anti-SOX17 (RD Systems, Minneapolis, MN, USA, cat. 
no. AF1924), mouse anti-GATA6 (RD Systems, Minneapolis, MN, USA, cat. no. MAB1700), goat 
anti-HNF1β (TCF-2) (RD Systems, Minneapolis, MN, USA, cat. no. AF3330), mouse anti-insulin IgG1 
(1/500, cat. no. I2018, Sigma-Aldrich, St. Louis, Missouri, USA), guinea-pig anti-porcine insulin 
(1/400, cat. no. A056401-2, Dako, Glostrup, Denmark), mouse anti-porcine glucagon (1/1000, G2654, 
Sigma-Aldrich, St. Louis, Missouri, USA), goat anti-urocortin 3 (1/200, cat. no. ab79121, Abcam, 
Cambridge, United Kingdom), and rabbit anti-NKX6.1 (1/100, cat. no. NBP1-82553, Novus, St. Louis, 
MO, USA). Cells were washed three times with 1× PBS and incubated with a mix of DAPI (1/1000, 
cat. no. D1306, Molecular Probes, Eugene, OR, USA) and corresponding secondary antibodies 
(1/500) in a dark wet chamber at room temperature for 1 h. The following secondary antibodies were 
used: goat anti-mouse IgG1 A488, goat anti-guinea-pig A488, goat anti-mouse IgG1 A647, goat 
anti-guinea-pig A546, donkey anti-rabbit A647, and donkey anti-goat A647 (Molecular Probes, 
Eugene, OR, USA). Cells were washed three times with 1× PBS and mounted in Prolong Diamond 
Antifade Mountant Media (cat. no. P36970, Life Technologies, Carlsbad, CA, USA). Images were 
taken on a Leica TCS SP2 AOBS or Leica TCS SP5 STED CW confocal microscopes (Leica 
Microsystems, Wetzlar, Germany). No specific feature of the original data was obscured, eliminated 
or misrepresented. 
2.7. Statistical Analyses 
Unless otherwise specified, Mann–Whitney U tests were applied to graphed data using Prism 
8.2.0 software (GraphPad Software Inc., La Jolla, California, USA). In figures, data are represented as 
mean ± SD. 
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3. Results 
3.1. Stepwise In-Vitro Differentiation of HNF4α+/Δ-hiPSCs to Hormone-Producing Pancreatic Islet Cells  
To address the mechanism of monogenic diabetes development, we previously established an 
in-vitro model based on derivation of several human induced pluripotent stem cell lines using 
fibroblasts from patients with MODY1 (maturity-onset diabetes of the young 1), carrying in a 
heterozygous state the p.Ile271fs mutation in HNF4α gene [20,21]. To monitor the adaptive variation 
of the miRNA signature, we used three different lines of MODY1-hiPSC generated from healthy (C) 
individuals and HNF4α mutation carriers (HNF4α+/Δ). We differentiated these lines towards 
hormone-producing maturing pancreatic islet cells (Figure 1A) by using a modification of a 
published seven-stage differentiation protocol [27,28]. Immunofluorescence staining confirmed 
expression of insulin, urocortin 3 and glucagon at the end of the differentiation protocol (day 28; 
Figure 1B). Samples were collected at each stage, and the miRNA expression was analyzed in 36 
samples, including one to six replicates of hiPSCs differentiated toward pancreatic islet-like cells 
(stages 1–7). RNA was isolated from pelleted cells, and profiling for 798 miRNAs was performed 
using a Nanostring human miRNA panel (NS_H_miR_v3a). After quantile normalization, we 
identified between 263 and 541 miRNAs expressed in each of our conditions, with fewer miRNAs 
expressed at earlier stages of differentiation (Figure 1C). This could be explained by an increase in 
the complexity of the cell content, but also by increased heterogeneity of the cells undergoing 
differentiation in response to the added exogenous stimuli [21,29]. To briefly assess the miRNAs 
expressed during the differentiation, we selected several known markers for definitive endoderm 
(SOX17), posterior foregut (GATA6, HNF1B) and pancreatic endocrine precursors (NKX6.1) and 
searched TargetScan to identify their regulatory miRNAs (Figure 1D). The identified regulatory 
miRNAs (hsa-miR-141-3p and hsa-miR-200a-3p for SOX17; hsa-miR-124-3p for GATA6; hsa-miR-217 
for HNF1B) showed, as expected, increased levels in later differentiation stages when targeted 
transcripts are expected to be downregulated (Figure 1D). The levels for hsa-miR-190b and 
hsa-miR-190a-5p (predicted to act on NKX6.1) are also raised and this might indicate a 
heterogeneous population in the later stages of differentiation. Of note, as previously reported by us 
[21], we observed no difference between healthy siblings and HNF4α mutation carriers regarding 
the production of insulin-positive cells, assessed here by immunostaining or by number of insulin 
transcripts (Figure 1E).  
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Figure 1. Differentiation of hiPSC towards pancreatic hormone-producing cells. (A) Step-wise 
differentiation scheme including the compounds used. (B) Immunostaining of maturing islet cells 
(stage 7) producing insulin (red); glucagon (green) and urocortin 3 (cyan). (C) Number of miRNAs 
expressed in the two conditions analyzed at each differentiation stage (n = 1–3 samples per stage for 
controls; n = 2–6 samples per stage for HNF4α+/Δ) (D) Immunostaining of SOX17 (definitive 
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NKX6.1 (islet Β-cells). Middle panels depict the main miRNAs targeting the above-listed markers. 
Normalized read counts of selected miRNAs during differentiation in HNF4α+/Δ or normal (blue) 
cells. Scale bars = 25 µm. (E) Immunostaining of insulin. 
3.2. The miRNAs’ Regulation Patterns Define Two Distinct Windows of Differentiation  
To assess the samples variation, we generated a Principal Component Analysis (PCA) (Figure 
2A), which identified a clear segregation of samples according to the differentiation interval 
(Principal Component 1: 23.25%, X-axis). Moreover, it revealed the separation of samples based on 
the HNF4α+/Δ mutation status (Principal Component 2: 11.31%, Y-axis). 
The hierarchical clustering reconfirmed these observations (Figure 2B), clustering the samples 
into two distinct main branches corresponding to early differentiation (stages 1 to 3) and late 
differentiation (stages 4 to 7) periods, with the mutation status being secondary to this separation.  
Based on these assays, we addressed the miRNA regulation pattern during differentiation. The 
analysis revealed that, indeed, many miRNAs changed their dynamic between the first (S1–3) and 
the last (S4–7) stages of differentiation, a period corresponding to the posterior foregut (stage 3) to 
pancreatic endoderm (stage 4) transition (Figure 2C,D). Interestingly, while in the healthy 
differentiating cells, more miRNAs were upregulated during the early stages of differentiation 
(31/52); the HNF4α+/Δ cells exhibited opposing regulation, with most miRNAs (47/63) being 
upregulated during the late stages, indicating a strong involvement of the HNF4α+/Δ mutation 
during the final stages of differentiation. 
3.3. The HNF4α+/Δ Mutation Status Modulates the miRNA Landscape in a Period-Dependent Manner  
To focus on the miRNA landscape changes caused by the HNF4α+/Δ mutation, we subsequently 
selected miRNAs exhibiting significant global differences between HNF4α+/Δ (MODY1) patients and 
their corresponding healthy controls during: 1) early (Class A, Table S1) or 2) late stages of 
differentiation (Class B, Table S1) (Figure 3A). We considered only the miRNAs having a normalized 
level of expression of at least 1 in at least one condition of the comparison. Class A consisted of 33 
differentially expressed miRNAs (DEmiRs) between HNF4α+/Δ and control-derived cells (Figure 
3B,C). Almost two thirds of these (63.63% 21/33) were downregulated in the mutation carrier cells 
(i.e., presenting higher expression in the control-derived samples). Of note, during late 
differentiation (Class B), there were three times more miRNAs deregulated as a consequence of 
HNF4α+/Δ mutation (3.15x, 104 vs. 33) (Figure 3B,C). Moreover, in contrast with the previous 
condition, these were largely upregulated (70.19% 73/104), indicating that, at later stages during 
differentiation, the mutation is either inducing miRNA production or impedes mechanisms 
involved in their degradation (Figure 3B). Finally, ten miRNAs were significantly regulated between 
the HNF4α+/Δ mutation and control during both periods (i.e., all along the differentiation timeline, 
Figure B,C). 
3.4. During Early Differentiation, HNF4α+/Δ Mutation Impacts miRNAs Involved in Cell Cycle Regulation 
and Consequently Pancreatic Endoderm Cell Fate Acquisition  
Subsequently, to understand the putative function and the impact of the miRNA changes 
characterizing the HNF4α+/Δ, we explored the global DEmiRs landscapes of the two differentiation 
windows using the Ingenuity Pathway Analysis software (Figure 4A). As expected, the analysis 
revealed cellular development and cell growth and proliferation in the top molecular and cellular 
functions of the DEmiRs characterizing the early differentiation period (Class A, Figure 4B). 
Interestingly, it also identified digestive and hepatic system development as leading physiological 
functions. These results suggest that the HNF4α+/Δ mutation affects the miRNAome early during 
differentiation and these differences already impact on the acquisition of the pancreatic endoderm 
cell fate. Furthermore, the network analysis of this miRNA set defined two distinct interconnected 
networks cantered on TP53 (Network 1)—a key cell cycle checkpoint regulator and AR (Androgen 
Receptor, Network 2)—a nuclear receptor involved in the regulation of cell cycle and senescence 
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(Figure 4C and Supplemental Figure S1A). Interestingly, almost half of the deregulated miRNAs 
(45.45% 15/33) were networked around and under the regulation of TP53 (Figure 4D), implying their 
involvement in cell proliferation/differentiation.  
3.5. HNF4α+/Δ Mutation Modulates miRNAs Involved in Cell Survival and Metabolic Processes during Late 
Differentiation  
The pathway analysis of the Class B miRNAs (i.e., differentially expressed between mutation 
carriers and controls during late differentiation) predicted cell cycle as well as cell death and 
survival as the top molecular and cellular functions (Figure 4E). Moreover, embryonic development 
was selected as the lead physiological function. In accordance, the network analysis defined several 
interconnected independent networks (Figure 4F) centered on Ago2 (Network 1, Supplemental 
Figure S1B), a protein involved in miRNA processing, TP53 (Network 2, Supplemental Figure S1C), 
TNF (Network 3, Figure 4G), an important hub for inflammation and metabolic processes, and 
BCL2L1 Network 4, Supplemental Figure S1D), a critical apoptosis regulator. These data indicate 
that the miRNA deregulated at later differentiation points as a result of the HNF4α+/Δ mutation are 
involved in a broader range of processes as compared to their Class A counterparts. Moreover, the 
common centering on TP53 (network 1 Class A and network 2 Class B) indicates the involvement of 
miRNAs regulated during both differentiation windows.  
3.6. Transcriptome–miRNAome Analysis Revealed that miRNAs Deregulated in HNF4α+/Δ Cells during Early 
Differentiation Cooperatively Target Critical Regulatory Hubs of Differentiation  
To expand our analysis of the processes and cellular networks affected by the changes induced 
by HNF4α+/Δ mutation in the miRNA landscape, we combined our previous analysis with a parallel 
global transcriptomics assay performed on the exact same samples (Figures 5 and 6). Globally, 681 
genes were differentially expressed (DEGs) between HNF4α+/Δ mutation and controls during the 
early period of differentiation (Figure 5A). The pathway analysis revealed that these genes were 
involved in glucose metabolism, p53 signaling and protein biosynthesis (Figure 5B). Interestingly, 
the program inferred the inactivation of glycolysis, gluconeogenesis, and AMPK signaling, 
suggestive of low protein biosynthesis. In contrast, p53 signaling was predicted as activated, 
indicative of increased cell cycle arrest of the HNF4α+/Δ cells and potentially apoptosis. This 
observation was further confirmed by TP53 being predicted as the top upstream regulator 
responsible for the observed regulatory landscape. Moreover, MYC, a potent transcriptional 
regulator of cell cycle genes, was predicted to be inactivated. 
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Figure 2. Analysis of the miRNAome during differentiation. (A) PCA plot of the conditions 
analyzed. (B) Hierarchical clustering of normalized miRNA expressed during the first seven stages 
of differentiation in HNF4α+/Δ and control-derived cells. (C) Number of miRNAs differentially 
expressed between early (S1–3) and late differentiation (S4–7) in either control- (left) or HNF4α+/Δ 
−derived cells (right), n = 1–6 samples per stage. (D) Selected representative RNAs’ regulation 
patterns. Graphs’ data are given as mean ± SD. 
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Figure 3. Comparative analysis of HNF4α+/Δ and control miRNAome during the early and late 
differentiation windows. (A) Experimental design of the condition pairs compared. (B) Number of 
miRNAs differentially expressed between HNF4α+/Δ and control cells during either early or late 
differentiation. (C) Selected representative RNAs’ regulation patterns (n = 1–3 samples per stage for 
controls; n = 2–6 samples per stage for HNF4α+/Δ). Boxed areas are showing the regulation switch 
after stages 1-3 for early differentiation effects (left boxes) and stages 4-6 for late differentiation 
effects (right boxes). Graphs’ data are given as mean ± SD. 
Biomedicines 2020, 8, 179 12 of 20 
 
 
Figure 4. Pathway analysis of the differentially expressed miRNAs between the HNF4α+/Δ mutation 
and control cells. (A) Experimental design of the condition pairs compared. (B) IPA-generated tables 
of the top molecular and cellular function (developmental cellular processes are marked by the red 
box, gene expression by purple box) and physiological system development and function for the 
differential miRNA landscape during the early differentiation period (red box marks the endocrine 
development signature). (C) IPA-generated overlapping networks. (D) IPA-generated network. (E) 
IPA-generated tables of the TOP molecular and cellular function and physiological system 
development and function for the differential miRNA landscape during the late differentiation 
period (proliferation /survival cellular processes are marked by the red box). (F) IPA-generated 
overlapping networks. (G) IPA-generated network. 
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Besides being predicted as the leading transcription regulator (position 3, Table 2), SOX2 was 
also observed to be downregulated (−3.801x) in our assay, suggesting that HNF4α+/Δ cells are more 
prone to exit pluripotency and engage in differentiation.  
Table 2. Top upstream regulators predicted by IPA acting in early differentiation stages. 
Name p-Value Details 
TP53 6.82 × 10-25 Transcription regulator 
HIF1A 2.62 × 10-24 Transcription regulator 
SOX2 9.15 × 10-23 Transcription regulator 
EGLN 7.76 × 10-22 (group) 
MYC 1 6.25 × 10-19 (-3.604 activation z- score) 
1 inferred to be inactivated by IPA. 
We subsequently used IPA and combined the miRNA and their corresponding gene targets 
differentially expressed between HNF4α+/Δ and control samples during the early differentiation 
window. Due to the large amount of data generated, for this study we focused on the top regulatory 
network characterizing the analyzed landscape (Figure 5C). 
The analysis indicated two convergence nodes centered on homeotic genes, each of these being 
regulated by six distinct DEmiRs (two in common). The first group of miRNAs, centered on HOXA1 
(converging red arrows on the interactome), exhibited mixed regulation (three upregulated, three 
downregulated). Nevertheless, the resulting observed downregulation of HOXA1 transcription 
suggests an active repression result (Figure 5D), implying their role in regulating retinoic acid 
(RA)-induced differentiation. 
The second group of DEmiRs are centered on SALL4 (Sal-like protein 4, converging orange 
arrows). This is a transcription factor with a known critical role in stemness maintenance [30–32]. All 
but one (5/6) of the miRNAs targeting this node are observed upregulated in the HNF4α+/Δ as 
compared to the control samples. This correlates with the observed downregulation of SALL4 gene 
expression (Figure 5E). In contrast, other transcriptional regulators, such as OTX2 or HOXB1, were 
targeted by just a single DEmiR of the dataset. Furthermore, several DEmiRs targeted multiple 
distinct nodes, such as miR-3180 (observed downregulated) and mir-491-5p (observed upregulated) 
with six and five gene targets, respectively.  
Globally, these data suggest that the HNF4α+/Δ cells differentiate earlier than their control 
counterparts; nevertheless, a wider study of the top networks and gene candidates should be 
performed to further confirm this observation. 
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Figure 5. Pathway analysis of the mRNA–miRNA landscapes during the early differentiation period. 
(A) Experimental design. (B) IPA-generated top canonical pathways (absolute value z-score > 1) (C) 
miRNA–mRNA interactions of the top transcriptional landscape network. (D) Expression levels of 
miRNAs targeting the HOXA1 node and its respective expression level at stage 3 (n = 3 samples for 
controls; n = 6 samples for HNF4α+/Δ). (E) Expression levels of hsa-miR-214-3p and hsa-miR-3180 and 
their target SALL4 expression at stage 3 (n = 3 samples for controls; n = 6 samples for HNF4α+/Δ). 
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Figure 6. Pathway analysis of the mRNA–miRNA landscapes during the late differentiation period. 
A) Experimental design. B) IPA-generated top canonical pathways (absolute value z-score greater 
than 1). C) miRNA–mRNA interactions of the top transcriptional landscape network. D) Transcript 
expression levels of the interaction nodes: TP53, PHLDA3 and LRRC17 at stages 5, 6 and 7 in 
HNF4α+/Δ (light orange) and control (green) lines (n = 2–6 samples per time-point). 
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3.7. The mRNA-miRNA Interactome of HNF4α+/Δ Cells during the Last Stages of Differentiation Confirms the 
Involvement of DEmiRs in Cell Cycle Regulation Arrest 
Similar to the above global transcriptome analysis during early differentiation, we addressed 
the transcriptional landscape characterizing the HNF4α+/Δ cells during late differentiation (Figure 
6A). The pathway analysis of the 364 DEGs between HNF4α+/Δ and control cells (FC ≥ 2, p < 0.05) 
inferred that pathways involved in transducing cellular stress (such as GP6 and the Amyotrophic 
Lateral Sclerosis Pathway), cell survival (such as the Adrenomedullin Signaling Pathway, the 
activation of which is linked to growth stimulation and apoptosis inhibition) and differentiation 
(such as Wnt/β–catenin signaling) were all predicted to be activated based on the observed 
transcriptome landscape (Figure 6B). In agreement, critical transcription factors for differentiation 
and development, such as SOX2, β-catenin (CTNNB1) and EOMES, were selected as top upstream 
regulators (Table 3), with β-catenin being the top predicted activated molecule of the assay 
(activation z-score 3.235).  
Table 3. Top upstream regulators predicted by IPA acting during late differentiation stages. 
Name p-Value Molecule Type 
SOX2 5.86 × 10-12 Transcription regulator 
CTNNB1 1.70 × 10-10 Transcription regulator 
HNRNPA2B1 1.61 × 10-09  
EOMES 1.22 × 10-08 Transcription regulator 
TAF4 3.51 × 10-08  
Of note, the program pinpointed HNF4α inhibition as a top regulator responsible for the 
observed landscape (Table 4).  
Table 4. Top upstream transcription regulators predicted by IPA to be inhibited in during late 
differentiation. 
Name Molecule Type p-Value Activation Z-Score 
EOMES Transcription regulator 1.22 × 10-08 -2.496 
REST Transcription regulator 4.33 × 10-04 -2.189 
HNF4α Transcription regulator 7.46 × 10-02 -2.000 
As before, by using IPA, we focused our analysis on the leading regulatory network 
characterizing the global transcriptional signature of HNF4α+/Δ cells and matched the DEmiRs to 
their corresponding networked DEGs (Figure 6C). Of interest, the main network centered on TP53, 
which was observed to be upregulated in the assay (Figure 6D), once more indicating increased cell 
cycle arrest in the HNF4α+/Δ samples.  
Although the capping value for network size was the same for both early and late 
differentiation analyses (35 molecules), the interactome of the latter revealed multiple convergence 
nodes, defined by targets aimed at by at least four different DEmiRs (8 as compared to 2). As such, 
PHLDA3 (observed upregulated, blue converging arrows), a p53-regulated AKT signaling repressor 
with a role in apoptosis induction, is targeted by as many as 10 distinct DEmiRs (Figure 6C). 
Interestingly, the upregulation of this gene was also shown to be critical for blocking the growth of 
pancreatic neuroendocrine tumors via AKT inhibition [33]. 
A second node targeted by 10 different DEmiRs was centered on LRRC17 (observed 
upregulated, purple converging arrows, Figure 6C), with only one miRNA shared with the previous 
PHLDA3-centered set. LRRC17 was previously involved in the inhibition of differentiation in other 
systems [34,35].  
The central node of the network, TP53, was targeted by six distinct DEmiRs (red converging 
arrow). Interestingly, all the three nodes described above were targeted by an equal number of 
upregulated and downregulated DEmiRs, suggesting additional levels of complexity modulating 
the target molecules. 
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Overall, these data suggest that HNF4α+/Δ cells further undergo p53-regulated cell cycle arrest, 
evolving from predicted regulation during the early differentiation window to experimentally 
confirmed observations during the late stages.  
4. Discussion 
To the best of our knowledge, this is the first differentiation-wide investigation addressing the 
miRNAome of MODY1 patient-derived islet-like cells and thus the impact of HNF4α+/Δ mutation at 
post-transcriptional levels. Previous studies involving MODY1 patients bearing the same mutation 
did not cover miRNA regulation [21,22]. However, one study [22] also pinpointed affected foregut 
endoderm gene expression signatures in the HNF4α+/Δ cells, although it employed a different 
differentiation protocol. We also previously showed that the heterozygous state of HNF4α mutation 
does not interfere with the acquisition of the β-cell fate in hiPSC-derived islet-like cells (S6 and S7) by 
using global proteomics [21]. Moreover, HNF4α plays a crucial role in vivo in restricting the 
pancreatic endocrine cell fate towards a monohormonal choice [23].  
In this study, we compared the miRNAome of differentiating hiPSC cells derived from 
HNF4α+/Δ mutation carriers (MODY1) and their family control along the differentiation timeline. The 
analysis of miRNA modulations highlighted a steep difference in the regulation pattern occurring 
during the transition from the posterior gut to pancreatic endoderm, defining an early and a late 
differentiation regulatory window. The number of miRNAs differentially expressed between 
HNF4α+/Δ cells and their corresponding controls increased from early to late differentiation, 
suggesting a more important impact of the mutation following the acquisition of the pancreatic 
progenitor fate. The pathway analysis of the miRNAome, transcriptome and miRNA–mRNA 
interactome revealed a likely gradual involvement of HNF4α+/Δ mutation in p53-mediated cell cycle 
arrest, with consequences for the proliferation potential, survival and cell fate acquisition of the 
differentiating cells. Judging by the miRNA interaction partners’ regulation, the cell cycle arrest 
seems to promote premature differentiation during early differentiation; however, this needs to be 
formally proved by future studies. 
It should be stated that, due to the numerous miRNAs having potential to regulate the same 
target [36], clear conclusions about each miRNA’s function and its transcript partner are difficult to 
reach. Moreover, many of the miRNA transcript partners are based on theoretical inference and 
were never demonstrated experimentally, so it is entirely possible that some DEmiR–DEG 
interactions are only possible at a theoretical level. In addition, it should be considered that the 
effects of HNF4α+/Δ mutations on the miRNAome profile could be direct, but also indirect, through 
the many HNF4α target genes. Even more, some of the miRNA regulations observed in this study 
could arise as a compensatory response to HNF4α+/Δ-based changes in gene expression. 
Nevertheless, our study clearly indicates that there is no evident master miRNA involved in 
regulating gene expression in response to HNF4α+/Δ mutation, but a larger subset of critical, possibly 
redundant, miRNAs. Consequently, validating the miRNA–target gene interactions in this context 
will require tedious work involving demultiplexing the collective effects of potentially redundant 
miRNAs, exhibiting different regulations and colliding on the same target. Thus, any future 
attempts for “rescuing” the regulation should probably be focused at multiple miRNA targets. 
Moreover, it should be considered that tampering with the p53 machinery and thus cell cycle control 
components will heavily impact on cell molecular signature and function, with consequences far 
beyond HNF4α-mutation-induced changes in the miRNA signature. Additionally, due to the high 
redundancy of the cell cycle control mechanisms, the deregulation of more than one miRNA will 
probably be required, increasing the difficulty of demultiplexing the observed changes and 
especially of reliably connecting them to the HNF4α-induced change in the pattern of a certain 
miRNA. 
The in-vitro character of the approach represents another inherent drawback of this study, as 
the observed landscape characterizes cells outside of their normal niche and in the absence of the 
typical in-vivo interactions. Moreover, the current experimental setup does not allow discriminating 
between the different cell subpopulations generated along the differentiation line. Hence, the 
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observed regulations represent the resultant heterogeneous cell population. It should also be 
considered that our analysis included only one HNF4α family—thus, one control and two affected 
individuals—due to the limited number of available samples. Moreover, the genetic background of 
siblings can differ significantly and, in order to reduce noise, it would be preferable to use isogenic 
controls generated using genome-editing tools (i.e., CRISPR-Cas9 technology) rather than family 
controls in any future study. Nevertheless, we expect that valuable information can be inferred from 
the present study, limiting the number of potential miRNA targets to be experimentally validated in 
a future study focused on knockdown/knockout of selected miRNA in transgenic animal models, in 
order to further elucidate the disease mechanism in MODY1. We expect that, pending experimental 
validation, certain miRNAs deregulated in the HNF4α+/Δ cells involved in cell cycle arrest on 
multiple targets, such as miR-3180, miR-1972 and let-7a-5p, could prove useful for therapy or in 
preventing the onset of MODY1. Moreover, the miRNA signature of healthy cells presented here 
could also provide a good reference for other studies focusing on different aspects of endocrine 
differentiation.  
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Supplemental Figure 1: A) IPA	generated	network	of	the	differentially	expressed	
miRNAs between the HNF4α+/Δ	 mutation	 and	 control	 cells	 during	 early	
differentiation.	 	 B-D)	 IPA	 generated	 networks	 of	 the	 differentially	 expressed	
miRNAs between the HNF4α+/Δ	 mutation	 and	 control	 cells	 during	 the	 late	
differentiation	window.	 
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hsa-miR-517c-3p+hsa-miR-
519a-3p	 hsa-miR-1972	 hsa-miR-521	 hsa-miR-518b	
hsa-miR-572	 hsa-let-7d-5p	 hsa-miR-1261	 hsa-miR-146b-5p	
hsa-miR-1307-5p	 hsa-miR-212-3p	 hsa-miR-770-5p	 hsa-miR-142-3p	
hsa-miR-520a-5p	 hsa-miR-548ah-5p	 hsa-miR-1236-3p	 hsa-miR-941	
hsa-miR-373-3p	 hsa-miR-498	 hsa-miR-514a-3p	 hsa-miR-181b-2-3p	
hsa-miR-223-3p	 hsa-miR-512-5p	 hsa-miR-1307-5p	 hsa-miR-555	
hsa-miR-4485-3p	 hsa-miR-302a-5p	 hsa-miR-595	 hsa-miR-221-5p	
hsa-miR-1236-3p	 hsa-miR-373-3p	 hsa-miR-572	 hsa-miR-608	
hsa-miR-514a-3p	 hsa-miR-1307-3p	 hsa-miR-325	 hsa-miR-499a-5p	
hsa-miR-520c-3p	 hsa-miR-1323	 hsa-miR-3180	 hsa-miR-548d-5p	
hsa-miR-3180	 hsa-miR-488-3p	 hsa-miR-210-3p	 hsa-miR-138-5p	
hsa-miR-1257	 hsa-miR-329-3p	 hsa-miR-299-3p	 hsa-miR-1224-5p	
hsa-miR-142-3p	 hsa-miR-383-5p	 hsa-miR-320a	 hsa-miR-105-5p	
hsa-miR-1281	 hsa-miR-889-3p	 hsa-miR-651-5p	 hsa-miR-489-3p	
hsa-miR-608	 hsa-miR-760	 hsa-miR-577	 hsa-miR-330-3p	
hsa-miR-138-5p	 hsa-miR-301b-5p	 hsa-miR-122-5p	 hsa-miR-215-5p	
hsa-miR-325	 hsa-miR-542-3p	 hsa-miR-100-5p	 hsa-miR-760	








hsa-miR-1972	 hsa-miR-1185-1-3p	 hsa-miR-214-3p	 hsa-miR-330-5p	
hsa-miR-212-3p	 hsa-miR-2682-5p	 hsa-miR-491-5p	 hsa-miR-548ah-5p	
hsa-miR-548ah-5p	 hsa-miR-615-3p	 hsa-miR-10a-5p	 hsa-miR-1305	
hsa-miR-1298-5p	 hsa-miR-490-3p	 hsa-miR-181a-3p	 hsa-miR-212-3p	
hsa-let-7g-5p	 hsa-miR-4707-5p	 hsa-let-7g-5p	 hsa-miR-521	
hsa-let-7c-5p	 hsa-miR-409-5p	 hsa-let-7d-5p	 hsa-let-7i-5p	
hsa-miR-485-3p	 hsa-miR-377-3p	 hsa-let-7c-5p	 hsa-miR-199a-5p	
hsa-miR-299-5p	 hsa-miR-499a-5p	
	
hsa-let-7b-5p	
hsa-let-7f-5p	 hsa-miR-221-5p	
	
hsa-miR-378g	
hsa-miR-105-5p	 hsa-miR-1224-5p	
	
hsa-miR-1323	
hsa-miR-664b-3p	 hsa-miR-330-3p	
	
hsa-let-7a-5p	
hsa-miR-576-5p	 hsa-miR-146b-5p	
	
hsa-miR-206	
hsa-miR-324-3p	 hsa-miR-30a-5p	
	
hsa-miR-372-3p	
hsa-miR-10a-5p	 hsa-miR-345-5p	
	
hsa-let-7f-5p	
hsa-miR-491-5p	 hsa-miR-1260b	
	
hsa-miR-496	
hsa-miR-206	 hsa-miR-210-3p	
	
hsa-let-7g-5p	
hsa-miR-496	 hsa-miR-378g	
	
hsa-let-7c-5p	
hsa-miR-499a-5p	 hsa-miR-200a-3p	
	
hsa-miR-324-3p	
hsa-miR-221-5p	 hsa-miR-95-3p	
	
hsa-miR-4531	
hsa-miR-1224-5p	 hsa-miR-362-3p	
	
hsa-miR-383-5p	
hsa-miR-330-3p	 hsa-miR-483-3p	
	
hsa-miR-887-5p	
hsa-miR-146b-5p	 hsa-miR-141-3p	
	
hsa-miR-548y	
hsa-miR-95-3p	 hsa-miR-10b-5p	
	
hsa-miR-520a-5p	
hsa-miR-744-5p	 hsa-miR-10a-5p	
	
hsa-miR-432-5p	
hsa-miR-10b-5p	 hsa-miR-521	
	
hsa-miR-4485-3p	
	
hsa-miR-206	
	
hsa-miR-498	
	
hsa-miR-29c-3p	
	
hsa-miR-373-3p	
	
hsa-miR-381-3p	
	
hsa-miR-196a-5p	
	
hsa-miR-429	
	
hsa-miR-370-3p	
	
hsa-miR-555	
	
hsa-miR-514b-5p	
	
hsa-miR-330-5p	
	
hsa-miR-1197	
	
hsa-miR-496	
	
hsa-miR-139-3p	
	
hsa-miR-190a-5p	
	
hsa-miR-98-5p	
	
hsa-miR-337-5p	
	
hsa-miR-381-3p	
	
hsa-miR-491-5p	
	
hsa-miR-214-3p	
	
hsa-miR-433-3p	
	
hsa-miR-431-5p	
	 	 	
hsa-miR-1253	
	 	 	
hsa-miR-519d-3p	
	 	 	
hsa-miR-889-3p	
	 	 	
hsa-miR-181a-3p	
	 	 	
hsa-miR-888-5p	
	 	 	
hsa-miR-526a+hsa-miR-
518c-5p+hsa-miR-518d-5p	
	 	 	
hsa-miR-517c-3p+hsa-miR-
519a-3p	
	 	 	
hsa-miR-548e-5p	
	 	 	
hsa-miR-891b	
	 	 	
hsa-miR-654-5p	
	 	 	
hsa-miR-512-5p	
	 	 	
hsa-miR-329-3p	
	 	 	
hsa-miR-654-3p	
	 	 	
hsa-miR-1185-1-3p	
	 	 	
hsa-miR-4707-5p	
	 	 	
hsa-miR-563	
	 	 	
hsa-miR-585-3p	
	 	 	
hsa-miR-495-5p	
	 	 	
hsa-miR-1185-2-3p	
	 	 	
hsa-miR-615-3p	
	 	 	
hsa-miR-2682-5p	
	 	 	
hsa-miR-518e-3p	
	 	 	
hsa-miR-513a-3p	
	 	 	
hsa-miR-208b-3p	
	 	 	
hsa-miR-301b-5p	
	 	 	
hsa-miR-369-3p	
	 	 	
hsa-miR-4536-5p	
	 	 	
hsa-miR-363-5p	
	 	 	
hsa-miR-490-3p	
	 	 	
hsa-miR-515-5p	
	 	 	
hsa-miR-5196-3p+hsa-miR-
6732-3p	
	 	 	
hsa-miR-409-5p	
	 	 	
hsa-miR-525-5p	
	 	 	
hsa-miR-526b-5p	
	 	 	
hsa-let-7d-5p	
	 	 	
hsa-miR-377-3p	
	 	 	
hsa-miR-512-3p	
	 	 	
hsa-miR-433-3p	
	 	 	
hsa-miR-337-5p	
	 	 	
hsa-miR-181a-2-3p	
	 	 	
hsa-miR-196b-5p	
	
